TY - JOUR AU - Bacsur, Péter AU - Wetwittayakhlang, Panu AU - Resál, Tamás AU - Földi, Emese AU - Vasas, Béla AU - Farkas, Bernadett AU - Rutka, Mariann AU - Bessissow, Talat AU - Afif, Waqqas AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Lakatos, Péter László AU - Molnár, Tamás TI - Accuracy of the Pancolonic Modified Mayo Score in predicting the long-term outcomes of ulcerative colitis: a promising scoring system JF - THERAPEUTIC ADVANCES IN GASTROENTEROLOGY J2 - THER ADV GASTROENTER VL - 17 PY - 2024 PG - 11 SN - 1756-283X DO - 10.1177/17562848241239606 UR - https://m2.mtmt.hu/api/publication/34752035 ID - 34752035 N1 - First published online March 21, 2024 LA - English DB - MTMT ER - TY - JOUR AU - Miheller, Pál AU - Kristóf, Tünde AU - Bor, Renáta AU - Farkas, Klaudia AU - Golovics, Petra AU - Harsányi, László AU - Müller, Katalin Eszter AU - Milassin, Ágnes AU - Palatka, Károly AU - Schäfer, Eszter AU - Szamosi, Tamás AU - Sarlós, Patrícia AU - Molnár, Tamás TI - A fekélyes vastagbélgyulladás gyógyszeres és sebészeti kezelése JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - Supplement-1 SP - 37 EP - 64 PG - 28 SN - 0030-6002 DO - 10.1556/650.2024.33050 UR - https://m2.mtmt.hu/api/publication/34741931 ID - 34741931 N1 - Klinikai egészségügyi szakmai irányelv. Megjelenés dátuma: 2023. május 8. Érvényesség időtartama: 2026. március 31. Nincs jelölve levelező szerzőség a közleményen. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Magyar, Dániel AU - Fábián, Anna AU - Vasas, Béla AU - Nacsev, Krisztián AU - Dubravcsik, Zsolt AU - Bősze, Zsófia AU - Tóth, Tibor AU - Bacsur, Péter AU - Bálint, Anita AU - Farkas, Klaudia AU - Molnár, Tamás AU - Resál, Tamás AU - Bor, Renáta AU - Szepes, Zoltán TI - Szűrő kolonoszkópos vizsgálatok hatékonyságának és biztonságosságának értékelése a Szegedi Tudományegyetemen és a Bács-Kiskun Vármegyei Oktatókórházban 2019 és 2022 között [Analysis of efficacy and safety of colonoscopic screening program at the University of Szeged and the Bács-Kiskun County Teaching Hospital between 2019 and 2022] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 6 SP - 221 EP - 231 PG - 11 SN - 0030-6002 DO - 10.1556/650.2024.32979 UR - https://m2.mtmt.hu/api/publication/34635367 ID - 34635367 N1 - Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged, Hungary Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Belgyógyászati Klinika, Szeged, Hungary Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szent-Györgyi Albert Klinikai Központ, Patológiai Intézet, Szeged, Hungary Bács-Kiskun Vármegyei Oktatókórház, Kecskemét, Hungary Kálvária sgt. 57., 6725, Szeged, Hungary Export Date: 17 March 2024 CODEN: ORHEA Chemicals/CAS: midazolam, 59467-70-8, 59467-96-8 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Resál, Tamás AU - Bacsur, Péter AU - Pápista, M AU - Kata, D AU - Farkas, Bernadett AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Molnár, Tamás TI - P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - Supplement_1 SP - i1706 EP - i1707 PG - 2 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad212.1068 UR - https://m2.mtmt.hu/api/publication/34546005 ID - 34546005 LA - English DB - MTMT ER - TY - JOUR AU - Bacsur, Péter AU - Resál, Tamás AU - Farkas, Bernadett AU - Sarlós, P AU - Iliás, Á AU - Kata, Diána AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - Szepes, Zoltán AU - Molnár, Tamás AU - Farkas, Klaudia TI - P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - Supplement_1 SP - i1279 EP - i1280 PG - 2 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad212.0804 UR - https://m2.mtmt.hu/api/publication/34538619 ID - 34538619 LA - English DB - MTMT ER - TY - JOUR AU - Bacsur, Péter AU - Wetwittayakhlang, P AU - Resál, Tamás AU - Farkas, Bernadett AU - Rutka, Mariann AU - Bessissow, T AU - Afif, W AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Lakatos, Péter László AU - Molnár, Tamás TI - P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - Supplement_1 SP - i759 EP - i760 PG - 2 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad212.0486 UR - https://m2.mtmt.hu/api/publication/34533257 ID - 34533257 LA - English DB - MTMT ER - TY - JOUR AU - Szemes, Kata AU - Borbásné Farkas, Kornélia AU - Sipos, Zoltán AU - Bor, Renáta AU - Fábián, Anna AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Molnár, Tamás AU - Schafer, Eszter AU - Szamosi, Tamas AU - Salamon, Agnes AU - Vincze, Áron AU - Sarlós, Patrícia TI - Co-Administration of Proton Pump Inhibitors May Negatively Affect the Outcome in Inflammatory Bowel Disease Treated with Vedolizumab JF - BIOMEDICINES J2 - BIOMEDICINES VL - 12 PY - 2024 IS - 1 PG - 13 SN - 2227-9059 DO - 10.3390/biomedicines12010158 UR - https://m2.mtmt.hu/api/publication/34509107 ID - 34509107 N1 - Division of Gastroenterology, First Department of Medicine, Medical School, University of Pécs, 13 Ifjúság Street, Pecs, 7624, Hungary Institute of Bioanalysis, Medical School, University of Pécs, Pecs, 7624, Hungary First Department of Medicine, University of Szeged, Szeged, 6720, Hungary Department of Gastroenterology, Hungarian Defence Forces Military Hospital, Budapest, 1134, Hungary Balassa János Hospital, Szekszárd, 7100, Hungary Institute for Translational Medicine, Medical School, University of Pécs, Pecs, 7624, Hungary Export Date: 6 February 2024 Correspondence Address: Sarlos, P.; Division of Gastroenterology, 13 Ifjúság Street, Hungary; email: sarlos.patricia@pte.hu AB - Concomitant medications may alter the effect of biological therapy in inflammatory bowel disease. The aim was to investigate the effect of proton pump inhibitors on remission rates in patients with inflammatory bowel disease treated with the gut-selective vedolizumab. Patients from the Hungarian nationwide, multicenter vedolizumab cohort were selected for post hoc analysis. Primary outcomes were the assessment of clinical response and endoscopic and clinical remission at weeks 14 and 54. Secondary outcomes were the evaluation of the combined effect of concomitant steroid therapy and other factors, such as smoking, on remission. A total of 108 patients were identified with proton pump inhibitor data from 240 patients in the original cohort. Patients on steroids without proton pump inhibitors were more likely to have a clinical response at week 14 than patients on concomitant PPI (95% vs. 67%, p = 0.005). Non-smokers with IBD treated with VDZ were more likely to develop a clinical response at week 14 than smokers, particularly those not receiving PPI compared with patients on co-administered PPI therapy (81% vs. 53%, p = 0.041, and 92% vs. 74%, p = 0.029, respectively). We found that the use of PPIs in patients treated with VDZ may impair the achievement of response in certain subgroups. Unnecessary PPI prescriptions should be avoided. LA - English DB - MTMT ER - TY - JOUR AU - Huinink, Sebastiaan Ten Bokkel AU - Thomassen, Doranne AU - Steyerberg, Ewout W AU - Pauwels, Renske W M AU - Casanova, Maria J AU - Bouguen, Guillaume AU - Mak, Joyce W Y AU - Molnár, Tamás AU - Lobo, Alan J AU - Seidelin, Jacob B AU - Amiot, Aurelien AU - D'Haens, Geert AU - Rivière, Pauline AU - Guidi, Luisa AU - Bor, Renáta AU - Lin, Wei-Chen AU - Peyrin-Biroulet, Laurent AU - Gisbert, Javier P AU - van der Woude, C Janneke AU - de Vries, Annemarie C TI - Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease. Individual Participant Data Meta-Analysis of 309 patients from 12 studies TS - Individual Participant Data Meta-Analysis of 309 patients from 12 studies JF - JOURNAL OF CROHNS & COLITIS J2 - J CROHNS COLITIS VL - 18 PY - 2024 IS - 1 SP - 134 EP - 143 PG - 10 SN - 1873-9946 DO - 10.1093/ecco-jcc/jjad118 UR - https://m2.mtmt.hu/api/publication/34133671 ID - 34133671 AB - The risk of relapse after anti-tumour necrosis factor [TNF] therapy discontinuation in Crohn's disease patients with perianal fistulas [pCD] is unclear. We aimed to assess this risk.A systematic literature search was conducted to identify cohort studies on the incidence of relapse following anti-TNF discontinuation in pCD patients. Individual Participant Data were requested from the original study cohorts. Inclusion criteria were age ≥16 years, pCD as (co)indication for start of anti-TNF therapy, >3 doses, and remission of luminal and pCD at anti-TNF discontinuation. Primary outcome was the cumulative incidence of CD relapse using Kaplan-Meier estimates. Secondary outcomes included response to retreatment and risk factors associated with relapse as assessed by Cox regression analysis.309 patients from 12 studies in 10 countries were included. Median duration of anti-TNF treatment was 14 months [IQR 5.8 - 32.5]. Most patients were treated for pCD without active luminal disease [89%], received first line anti-TNF therapy [87%] and continued immunomodulatory following anti-TNF discontinuation [78%]. Overall cumulative incidence of relapse was 36% [95% CI 25-48%] and 42% [95% CI 32-53%] at 1 and 2 years after anti-TNF discontinuation. Risk factors for relapse included smoking [HR 1.5 (1.0, 2.1)] and history of proctitis [HR 1.7 (1.1, 2.5)]. Overall retreatment response rate was 82%.This IPD-MA, on predominantly patients with pCD without active luminal disease and first line anti-TNF therapy, shows that over half of patients remain in remission 2 years after anti-TNF discontinuation. Therefore, anti-TNF discontinuation may be considered in this subgroup. LA - English DB - MTMT ER - TY - JOUR AU - Resál, Tamás AU - Bacsur, Péter AU - Keresztes, Csilla AU - Bálint, Anita AU - Bor, Renáta AU - Fábián, Anna AU - Farkas, Bernadett AU - Katsanos, Kostas AU - Michalopoylos, George AU - Ribaldone, Davide Giuseppe AU - Attauabi, Mohamed AU - Zhao, Mirabella AU - Barak, Hadar Amir AU - Yanai, Henit AU - Bezzio, Cristina AU - Rispo, Antonio AU - Castiglione, Fabiana AU - Bar-Gil Shitrit, Ariella AU - Pugliese, Daniela AU - Armuzzi, Alessandro AU - Savarino, Edoardo Vincenzo AU - Kolar, Martin AU - Lukáš, Milan AU - Chashkova, Elena AU - Filip, Rafał AU - Rozieres, Aurore AU - Nancey, Stéphane AU - Krznarić, Željko AU - Schäfer, Eszter AU - Szamosi, A AU - Sarlós, Patrícia AU - Franko, Matej AU - Drobne, David AU - Knyazev, Oleg V AU - Kagramanova, Anna V AU - Limdi, Jimmy AU - Wetwittayakhlang, Panu AU - Lakatos, Péter László AU - Maharshak, Nitsan AU - Bannon, Lian AU - Nyári, Tibor András AU - Szepes, Zoltán AU - Farkas, Klaudia AU - Molnár, Tamás TI - Real-Life Efficacy of Tofacitinib in Various Situations in Ulcerative Colitis. A Retrospective Worldwide Multicenter Collaborative Study TS - A Retrospective Worldwide Multicenter Collaborative Study JF - INFLAMMATORY BOWEL DISEASES J2 - INFLAMM BOWEL DIS VL - In press PY - 2024 PG - 12 SN - 1078-0998 DO - 10.1093/ibd/izad135 UR - https://m2.mtmt.hu/api/publication/34089134 ID - 34089134 AB - Tofacitinib (TFB) appears to be effective in the treatment of ulcerative colitis (UC); however, available real-world studies are limited by cohort size. TFB could be an option in the treatment of acute severe ulcerative colitis (ASUC). We aimed to investigate efficacy and safety of TFB in moderate-to-severe colitis and ASUC.This retrospective, international cohort study enrolling UC patients with ≥6-week follow-up period was conducted from February 1 to July 31, 2022. Indications were categorized as ASUC and chronic activity (CA). Baseline demographic and clinical data were obtained. Steroid-free remission (SFR), colectomy, and safety data were analyzed.A total of 391 UC patients (median age 38 [interquartile range, 28-47] years; follow-up period 26 [interquartile range, 14-52] weeks) were included. A total of 27.1% received TFB in ASUC. SFR rates were 23.7% (ASUC: 26.0%, CA: 22.8%) at week 12 and 41.1% (ASUC: 34.2%, CA: 43.5%) at week 52. The baseline partial Mayo score (odds ratio [OR], 0.850; P = .006) was negatively associated with week 12 SFR, while biologic-naïve patients (OR, 2.078; P = .04) more likely achieved week 52 SFR. The colectomy rate at week 52 was higher in ASUC group (17.6% vs 5.7%; P < .001) and decreased with age (OR, 0.94; P = .013). A total of 67 adverse events were reported, and 17.9% resulted in cessation of TFB. One case of thromboembolic event was reported.TFB is effective in both studied indications. TFB treatment resulted in high rates of SFR in the short and long terms. Higher baseline disease activity and previous biological therapies decreased efficacy. No new adverse event signals were found. LA - English DB - MTMT ER - TY - JOUR AU - Farkas, Klaudia AU - Resál, Tamás AU - Bacsur, Péter AU - Farkas, Bernadett AU - Bálint, Anita AU - Fábián, Anna AU - Bor, Renáta AU - A., Shitrit AU - D., Pugliese AU - D., Drobne AU - H., Yanai AU - T., Szamosi AU - M., Lukas AU - A., Kagramanova P.L. Lakatos AU - N., Maharshak AU - G., Michalopoulos AU - S., Nancey AU - Z., Krznaric AU - Szepes, Zoltán AU - Molnár, Tamás TI - Real-life effectiveness of tofacitinib in two indications in ulcerative colitis: a retrospective worldwide, multicenter, collaborative study JF - UNITED EUROPEAN GASTROENTEROLOGY JOURNAL J2 - UEG JOURNAL VL - 11 PY - 2023 IS - S8 SP - 202 EP - 202 PG - 1 SN - 2050-6406 UR - https://m2.mtmt.hu/api/publication/34593738 ID - 34593738 LA - English DB - MTMT ER -